Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Impact of TAC chemotherapy on muscle composition in breast cancer patients
NL-OMON37832Not yet recruiting
- Sponsor
- Máxima Medisch Centrum
- Start
- Jun 2012
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of docetaxel, doxorubicin and cyclophosphamide in breast cancer, sponsored by Máxima Medisch Centrum. Primary endpoints: Change in muscle mass and Change in muscle fiber cross-sectional area. Planned start Jun 2012; status: not yet recruiting.
02
Drugs
docetaxeldoxorubicincyclophosphamide
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON37832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37832.